The Children’s Tumor Foundation partnered with Takeda Pharmaceuticals and six leading medical centers on a clinical trial called INTUITT-NF2, an innovative platform trial that evaluates multiple treatments simultaneously. This initiative is a result of the landmark work of our visionary Synodos for NF2 research collaborative, the NF2-SWN Accelerator Initiative, an investment from Takeda Pharmaceuticals, the participation of scientists at the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), and the vital Synodos NF2 leadership from Massachusetts General Hospital (MGH), Johns Hopkins University (JHU) and Indiana University (IU).
A direct outcome of this collaborative partnership and research initiative, spearheaded by the Children’s Tumor Foundation (CTF), found promising evidence that brigatinib can help shrink the tumors of patients with NF2-related schwannomatosis. Using a highly innovative phase II platform-basket trial design, the multi-center team found that brigatinib shrunk 10% of growing tumors and 23% of all tumors.
Driven by CTF’s mission to End NF, this alliance across the academic, pharma, and patient landscapes has shortened the time from initial research to active trial, thereby bringing promising treatment options to the NF2-SWN patients who need them.